CVAC News and Press, CureVac N.V. From 04/24/24

2024-04-24 15:12:02 ET CureVac N.V. (CVAC) Q4 2023 Earnings Conference Call April 24, 2024 09:00 AM ET Company Participants Sarah Fakih - Vice President of Corporate Communications & Investor Relations Alexander Zehnder - Chief Executive Officer Myriam Mendil...

Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary s...

Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, GERMA...

2024-04-23 14:08:22 ET More on CureVac BV CureVac: No Momentum In Sight CureVac, MD Anderson team up for cancer vaccines CureVac posts early efficacy results for GSK-partnered flu shot Seeking Alpha’s Quant Rating on CureVac BV Historical earni...

2024-04-23 10:25:34 ET Major earnings expected before the bell on Wednesday include: The Boeing ( BA ) Biogen ( BIIB ) General Dynamics ( GD ) AT&T ( T ) Thermo Fisher Scientific ( TMO ) Read the full article on Seeking Alpha For f...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business up...

2024-04-17 17:01:03 ET Gainers: Vanda Pharmaceuticals  ( VNDA ) +7% . Sutro Biopharma ( STRO ) +5% . CureVac  ( CVAC ) +5% . CorMedix  ( CRMD ) +4% . Bank OZK ( OZK ) +4% . Losers: Omega Therapeutics ( OM...

2024-04-16 07:59:04 ET More on CureVac BV CureVac: No Momentum In Sight CureVac posts early efficacy results for GSK-partnered flu shot Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for...

Agreement creates strong synergies between CureVac's unique end-to-end mRNA capabilities and MD Anderson's translational and clinical research expertise Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet ...

2024-04-04 08:20:35 ET More on CureVac BV CureVac: No Momentum In Sight Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for CureVac BV Read the full article on Seeking Alpha For f...